Background: World Health Organization recommend the use of isoniazid (INH) only, or INH and rifapentine therapy, to treat the latent tuberculosis infection (LTBI). The recent rise of isoniazid and multi-drug resistant (MDR) tuberculosis has complicated the choice of LTBI treatment regimen. The current lack of evidence on optimal regimens prevents the formulation of definitive recommendations for latent drug-resistant tuberculosis. We examine the risk of disease progression of individuals exposed to sensitive, INH, or MDR tuberculosis who received INH as part of routine tuberculosis management.
Introduction
The worldwide TB pandemic remains one of today's greatest global health challenges. The World Health Organization (WHO) estimates that there were 10.4 million new cases of TB in 2016 (1) . Between one third and a quarter of the world's population is estimated to have latent TB infection (LTBI) (2). Although treatment of LTBI has been shown to protect against the development of TB disease, only a tiny minority of those at risk receive preventive therapy (2).
WHO's recently revised guidelines on treating LTBI now recommend systematic testing and treatment of LTBI for an expanded group of people at high risk of TB progression including child and adults contacts of pulmonary TB patients. Recommended regimens for LTBI include 6 to 9 month isoniazid (INH), a 3-month regimen of rifapentine plus INH, 3-4 months INH and rifampicin, and 3-4 months rifampicin alone (2).
The recent rise of INH-resistant and multi-drug resistant TB has complicated the choice of an LTBI treatment regimen. Although several small studies have shown that regimens tailored to specific drug sensitivity profiles can be effective, most of these lacked control arms or compared these individually tailored regimens to no treatment rather than an alternative regimen (3) . WHO concludes that the current lack of evidence on optimal regimens prevents the formulation of definitive recommendations for INH-resistant and MDR-exposed contacts (2).
In countries that implement preventive therapy for those at high risk, close contacts of MDR-TB patients often receive standard LTBI regimens prior to time that the index patient's drug sensitivity tests are available to the treating clinician. In areas where rapid diagnostic tests for MDR are not yet available, contacts may receive INH for months prior to the eventual diagnosis of MDR (4, 5) . Here, we examined the risk of disease progression of individuals exposed to sensitive, INH or MDR-TB who received INH as part of routine TB management.
Methods

Recruitment
This study was conducted in Lima in 106 district health centers that provide care to a population of approximately three million residents. Patients were referred to study staff if they were over 15 years of age and had been diagnosed with pulmonary TB (PTB) disease by a health center clinician. We requested permission to visit each patient's household and recruit his or her household contacts (HHCs) into a prospective cohort study. Study workers aimed to enroll all household members within one week of the diagnosis of the index case.
Baseline assessment of index patients and household contacts
We collected the following data from index patients and HHCs at the time of enrollment: age, height, weight, gender, occupation, history of TB disease, alcohol, education, housing information, intravenous drug and tobacco history, symptoms of TB, BCG vaccination, and comorbidities including HIV and diabetes mellitus. For index cases, we additionally collected the duration of coughing symptoms before diagnosis, presence of cavitary disease, sputum smear status, and culture results. For those with positive cultures, isolated underwent drugsusceptibility test and MIRU-based genotyping (detail information in Supplement 1). For HHCs, we additionally collected whether IPT had been initiated and their relationship to the index patient. Household contacts with symptoms were referred to their local health clinic for chest radiography and clinical evaluation for active TB disease. Household members with no known history of active TB disease or previously documented infection received a tuberculin skin test.
INH preventive therapy for HHCs
The 2006 Peruvian National TB Program recommended that HHCs 19 years old or younger or those who had a specified comorbidity should receive 6 months of INH preventive therapy (IPT) (Ref 6 ) while those with HIV should receive 12 months. Children under 19 were offered IPT at the time index patients were diagnosed, regardless of whether they were infected or not. Health care providers often chose to discontinue IPT if the index patient to whom HHCs had been exposed was subsequently diagnosed with MDR-TB but some MDR-exposed HHCs received a full course of IPT. We used medical records from participating hospitals and health clinics to determine the duration of IPT.
Follow-up of household contacts
Participants were revisited in their household at 2, 6, and 12 months and were asked whether they had been diagnosed with TB or if they had had symptoms of active disease. Those who reported symptoms were referred to their local health center for further clinical evaluation including a chest radiograph and sputum smear.
Outcome definition
We identified incident TB among HHCs during scheduled household visits and from a systematic review of TB registries at the participating health clinics. We considered HHCs to have co-prevalent TB if they were diagnosed within 2 weeks of the diagnosis of the index case.
If HHCs were diagnosed between 2 weeks and 15 months after diagnosis of the index case, we considered them "secondary" cases. Diagnosis of adult secondary TB followed the same criteria as outlined above for index cases. We defined secondary TB disease among contacts younger than 18 years of age according to the consensus guidelines for classifying TB disease in children (7) .
Data categorization
The information of data categorization is provided in Supplement Appendix (Supplement 1)
Analyses
We included in our analysis only HHCs under 19 because older contacts were only offered IPT if they had comorbidities that substantially increased their risk of TB disease. We used a Cox frailty proportional hazards model to evaluate risk factors for incident TB disease, accounting for clustering within households (8) . We first performed a univariate analysis to examine the effect of IPT on TB incidence, followed by a multivariate model in which we adjusted for the age of the index case age and the age, social economic status (SES), and TB history of the HHC. To evaluate whether the effect of IPT on TB incidence varied by resistance profile of the index case, we added a variable representing INH resistance in the index case and an interaction term for INH-resistance and IPT. Because the spectrum of INH resistance-causing mutations that lead to INH mono-resistance may differ from those that lead to MDR-TB, we classified strains as sensitive, mono-INH-resistant, or MDR-TB (resistant to both INH and RIF). Previous studies have shown that the efficacy of IPT treatment is reduced if the treatment is ended within 3 months (9). We therefore repeated these analyses stratifying by a dichotomous variable that captured treatment for more or less than 3 months. We also considered the possibility that HHCs ≤ 5 years of age would be more likely to acquire TB at home than in the community compared to older contacts and we thus conducted sensitivity analyses restricted to this subgroup.
To determine whether the effect of IPT on disease in the HHCs was a function of the mean inhibitory concentrations (MICs) of the infecting organism, we repeated these analyses for the subset of HHCs exposed to index cases for whom quantitative INH-resistance was available.
Verifying our finding with an independent dataset
We conducted a seperate analysis using publically available data from an independent dataset collected from a prospective cohort study in South Lima and Callao, Peru between 2010 and 2013, posted by Grandjean et al. (10) . This study enrolled 1,055 HHCs of 213 MDR-TB index cases and 2,362 HHCs of 487 drug-susceptible index cases and measured incident TB over 2-years of follow-up. Drug susceptibility testing for INH and RIF was performed for all index cases' samples using microscopic observation drug susceptibility assays (11) in regional laboratories and results were confirmed in the national reference laboratory using proportions methods. The investigators note that IPT was discontinued in this group after MDR-TB index cases were confirmed but data on the duration of IPT were not available.
We applied the same analytic plan which we used for our own data to this independent dataset.
Results
Data collection
We enrolled 14,044 HHCs of 4,500 patients suspected of having PTB, of whom 12,767 had been exposed to index patients with microbiologically confirmed TB. Of these, 5,496 (43%) were ≤ 19 years of age. We restricted our analyses to 4,216 HHCs who were exposed to an index case whose INH resistant profile was available (Figure 1 ). At the time of enrollment, 2,106 HHCs (50%) had initiated IPT while the remainder had declined it. On average, the duration of IPT was shorter among HHCs of MDR-TB cases (115 days) than those of drug-sensitive TB (142 days) and mono-INH-resistant TB cases (148 days) (Figure 2 ). The baseline characteristics stratified by IPT are shown in Table 1 .
At 12-months follow-up, 146 HHCs developed TB disease. Of these, 48 (33%) had complete 24-loci MIRU-typing. Twenty-nine of the 48 (64%) had at least 23 loci that matched their index cases' MIRU-typing.
Univariate analyses and multivariate adjustment
In univariate analyses, we found that HHCs under age 15 who received IPT were less likely to develop TB disease compared to those who did not (HR=0.33, 95% CI = 0.22 to 0.48). The INHresistance profile of the index patient was not associated with subsequent disease in the HHCs (Table 2) . HHCs who received IPT experienced a lower incidence of secondary TB disease and this signal was retained after we adjusted for age, SES, and history of TB, as well as the age of the index case (adjusted HR=0.34, 95% CI = 0.23 to 0.5) ( Table 2) .
Adding IPT and INH-resistant profile of index case as interaction terms
We found that the protective effect of IPT was significantly stronger in HHCs exposed to drug- (Table 3C) . These results persisted when we restricted the analyses to HHCs ≤ 5 years of age among whom the protective effect of IPT was almost 100% effective among all those who received ≥ 3 months IPT treatment (Table 4A- 
Second independent dataset
The second dataset included 1,121 HHCs ≤ 19 years age who had available IPT data. Here again, we found that IPT strongly protected HHCs from incident TB in both the univariate and in an analysis that adjusted for age, SES, and TB history (HR = 0.1; 95% CI = 0.03 to 0.3). When we further evaluated whether the effect of IPT varied by the resistance pattern of index cases, we found that IPT not only protected HHCs of drug-sensitive index cases (adjusted HR= 0.13 95% CI = 0.03 to 0.57) but also perfectly protected 76 HHCs of MDR-TB index cases from developing TB.
Discussion
Here, we found that INH prevention therapy protected HHCs of index TB patients against TB disease even when the index patients were infected with MDR and mono-INH-resistant Mtb strains. This protective effect was greater among HHCs of MDR-TB cases than among those exposed to mono-INH resistant strains. As expected, the risk of incident TB was higher among HHCs who received less than 3 months treatment, especially among children under five. No child who received ≥ 3 months of IPT developed TB disease. We also showed that the effect of IPT in preventing TB progression is unrelated to the MIC of the index patient's TB strain; no HHC who was exposed to an index patient with a >5 μg/ml MIC developed disease. We verified our findings in a second independent dataset in which the protective effect of IPT against TB in HHCs of MDR-TB cases was also demonstrated. be measured as the regimens contained other drugs tailored to the drug susceptibility profile of the index strain. In that study, children who did not receive preventive therapy were four times more likely to develop TB disease (14) . A study conducted in Australia considered people who received IPT after exposure to MDR-TB as controls and compared them to MDR-TB contacts who received other regimens of preventive therapy or no treatment (15) . Of these, two contacts developed TB disease within 54 months, but the study did not specify what regimens these two incident patients received. Other studies reported the use of regimens that included INH for contacts of MDR-TB patients, but these studies lacked control arms and thus the efficacy of INH could not be measured (16) (17) (18) .
We considered several possible explanations for the protective effect of IPT on contacts of INHresistant TB patients. First, HHCs might have been infected in the community by index patients with drug-sensitive TB rather than by the patient with drug resistant TB living in their household and so their TB strains may have been susceptible to INH. However, MIRU-typing of the secondary cases showed that approximately two-thirds harbored strains that matched their index case, suggesting that no more than a third of the secondary cases acquired TB in the community.
If IPT had had no effect among HHCs of MDR-TB index cases, we would expect to see an protective effect of no less than 0.32 (effect size of contacts exposed to drug sensitive strains, table 3A), rather than the 0.26 effect we observed. Furthermore, the observed protective effect was stronger in under-5 year olds, whom we considered much less likely than older contacts to have been infected by someone other than the index case. In the independent dataset, Grandjean et al. noted that 86% of MDR-TB secondary cases were exposed to MDR-TB index cases, again suggesting that most of the incident MDR-TB among HHCs in their study were infected at home rather than in the community (10).
Secondly, we considered the possibility that HHCs who chose to take IPT came from higher SES groups and thus were less likely to develop TB disease, regardless of the resistance profile of the index case. Although we attempted to adjust for SES, it is possible the principal component score we used did not completely capture its effect. However, in this case, we would not expect the INH effect to vary by duration of therapy as it did in our study (Table 3 IPT has been used for decades in tuberculosis control efforts and despite some concerns about hepatoxicity, it has been shown to have a good safety profile especially in children. Health workers worldwide have extensive experience using this drug and handling its adverse effects.
Establishing its efficacy against latent MDR TB would therefore be of great value and could set a bar against which alternative treatment could be measured. For example, the ongoing PHOENIx trial, designed to establish the efficacy of delamanid against MDR-LTBI uses INH as the control arm. If investigators consider that INH is ineffective against MDR TB and is serving only as a placebo, the effect of delamanid could be underestimated (27).
Our study has some limitations. The contacts of MDR-TB cases received INH for a shorter period of time than contacts of pan-sensitive or mono-INH-resistant cases, presumably because clinicians halted IPT once the index patients' MDR-TB status were confirmed. Given the dose effect we observed, we would expect to see an even more extreme effect of IPT had contacts of MDR-TB cases received the same duration of IPT as those exposed to drug-sensitive strains.
Also, we were unable to assess the effect of IPT on adult contacts of MDR-TB cases given that IPT is not indicated for adult contacts without co-morbidities in Peru. Finally, almost all HHCs in our cohort were HIV-negative, so we were not able to evaluate the synergistic effect between IPT and highly active antiretroviral therapy in HIV-positive HHCs exposed to MDR-TB.
In conclusion, we found that IPT protected against TB among contacts of INH-resistant TB patients. Given the safety profile of INH and its wide use across the globe, INH may have a role in the management of MDR-LTBI.
